Dasher Neuroscience achève le recrutement des patients dans le cadre de l'essai clinique mondial de phase II portant sur le YA-101, son principal candidat-médicament développé grâce à l'IA, destiné au traitement de l'atrophie multisystématisée (AMS)

Phase 2YA-101Positive

AI Analysis

Summary

Dasher Neuroscience completed patient enrollment in a global Phase II clinical trial for YA-101, an AI-developed drug candidate for treating multiple system atrophy.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Patient recruitment completed in global Phase II clinical trial

Importance:6/10

Sentiment:

0.60

Phase 2AI-discovered drugCNSClinical trial milestoneDasher Neuroscience

Related Companies

$7829

Read the original article

Published by PR Newswire Biotech on July 29, 2026 7:01 AM

Read Original